Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 264.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.62M |
| Shares Out | 75.97M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,063,793 |
| Open | 3.450 |
| Previous Close | 3.460 |
| Day's Range | 3.400 - 3.625 |
| 52-Week Range | 1.350 - 4.600 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+144.25%) |
| Earnings Date | May 13, 2026 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 144.25% from the latest price.
News
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b l...
Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Tegoprubart showed non-inferior efficacy and a strong safety profile in kidney transplant studies, with promising results in islet cell transplantation and new Orphan Drug status for liver. Phase 3 planning is underway, targeting a large U.S. market, with a solid cash runway into next year.
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug desig...
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company a...
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Phase II and Ib studies demonstrated strong safety and promising efficacy for a new transplant therapy, with regulatory discussions and a phase III trial launch expected by year-end. Expansion into islet cell and xenotransplant programs is underway, supported by a solid cash runway through 2027.
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D.
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1....
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive prelimi...
Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Reports Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol...
Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Tegoprubart, an anti-CD40 Ligand antibody, showed strong safety and noninferiority to tacrolimus in a phase II kidney transplant trial, with plans for a phase III study and expansion into islet cell and xenotransplant indications. Clinicians praised the safety profile, while investors focused on missed superiority.
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of it...
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common ...
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The comp...
Eledon Pharmaceuticals Transcript: Study Result
The phase II BESTOW trial showed tegoprubart matched tacrolimus in preventing kidney transplant rejection, with numerically better kidney function and a superior safety profile, notably reducing diabetes, tremors, and hypertension. Plans are underway for a phase III trial and further long-term studies.
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart de...
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at Kidney Week
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025
Tegoprubart aims to replace tacrolimus in kidney transplants, showing superior kidney function and iBOX scores in early trials, with a favorable safety profile and treatable rejection rates. The concentrated U.S. market and upcoming phase II/III milestones position the program for significant value creation.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m 2 post-transplant for patients on tegoprubart Company on track to report topline...